Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced that senior management will participate in two upcoming investor conferences in October 2024 to discuss the company's progress in developing innovative therapeutics for fibro-inflammatory diseases. These presentations will provide updates on Chemomab's lead drug candidate, CM-101, and its potential to address unmet needs in diseases such as primary sclerosing cholangitis (PSC) and systemic sclerosis.
Investor Conference Details
Chemomab management will meet with investors at the Third Annual ROTH Healthcare Opportunities Conference in New York City on October 9, 2024. Additionally, Chemomab co-founder and Chief Executive Officer Dr. Adi Mor will participate in a fireside chat with senior biotechnology analyst Michael Okunewitch at the Maxim Healthcare Virtual Summit on October 16, 2024, at 9:00 am ET. A recording of the Maxim Healthcare Summit fireside chat will be available via a link on the Chemomab investor relations website after the conference completes.
CM-101: Targeting CCL24 in Fibro-Inflammatory Diseases
Chemomab is focused on developing CM-101, a dual-activity monoclonal antibody that neutralizes CCL24 activity. CCL24 is a soluble protein that plays a significant role in promoting fibrosis and inflammation. Preclinical and clinical studies have shown that CM-101 has a favorable safety profile and is generally well-tolerated, suggesting its potential to treat multiple severe and life-threatening fibro-inflammatory diseases.
Clinical Progress and Upcoming Milestones
Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on promising data from its Phase 2 trial in PSC, the company anticipates two key milestones in early 2025, including feedback from the FDA on the design of its planned Phase 3 registrational trial. CM-101 has been granted Orphan Drug and Fast Track designations by the FDA and Orphan Drug designation by the EMA for the treatment of PSC. Furthermore, Chemomab's CM-101 program for systemic sclerosis is Phase 2-ready with an open U.S. IND.
